The emergence of viral pandemics, exemplified by the Coronavirus Disease (COVID-19), has exposed the urgent need for the development of viral infection therapeutics. In a short span of time, more than 1.5 million individuals have been infected and there have been nearly 90, 000 deaths worldwide. Our objective is to pharmacologically validate a new strategy […]

COVID-19 pandemic has brought the world to standstill with more than 3 million people infected and more than 200 000 mortality so far. It has literally brought the health care systems in many countries to the breaking point, if not beyond. The economic consequences have been devastating with millions of people out of work. We […]

The recent outbreak of the SARS-CoV-2 associated coronavirus disease, COVID-19, had been declared a global pandemic by the World Health Organization. There is still only a minimal understanding of the virus and an absence of effective targeted therapy for its treatment. Epigenetic regulations in cells control the expression of genes without modifications to the genetic […]

The novel SARS-Coronavirus-2 becomes activated and is infective after interacting with the human TMPRSS2 enzyme, as it primes the virus to enter and hijack lung cells for viral replication. By designing drugs using a strategy that has shown success in inhibiting enzymes structurally similar to TMPRSS2 and understanding the exact shape of this enzyme in […]

The effectiveness of cancer drugs depends on several factors which are governed by the genetic and ‘epigenetic’ code of cancer cells. The epigenetic code comprises those heritable modifications that bookmark DNA and DNA-associated proteins to guide the expression of genetic attributes without changing the DNA sequence. This epigenetic code is written, read, and erased by […]

Medulloblastoma (MB) is the most common childhood brain cancer. Current treatment for these tumors is invasive involving irradiation of the entire brain and spine. Although some types of MB respond well, others have an abysmal prognosis, and the lack of less invasive therapies means that children undergoing treatment suffer from severe developmental defects and reduced […]

The Structural Genomics Consortium (SGC) is a not-for-profit public-private partnership research organization that aims to accelerate the discovery of new medicines through open science. This Mitacs cluster will bring together SGC’s industry and academic collaborators to work together towards new and affordable medicines for challenging diseases. Sixty-three post-doctoral fellows will spend 2-3 years developing open […]

COVID-19 pandemic has brought the world to standstill with more than 55 million people infected to-date and more than 1.34 million mortality so far. It has literally brought the health care systems in many countries to the breaking point, if not beyond. The economic consequences have been devastating with millions of people out of work. […]

The Structural Genomics Consortium (SGC) is a not-for-profit public-private partnership research organization that aims to accelerate the discovery of new medicines through open science. This Mitacs cluster will bring together SGC’s industry and academic collaborators to work together towards new and affordable medicines for challenging diseases. Sixty-three post-doctoral fellows will spend 2-3 years developing open […]

The Structural Genomics Consortium (SGC) is a not-for-profit public-private partnership research organization that aims to accelerate the discovery of new medicines through open science. This Mitacs cluster will bring together SGC’s industry and academic collaborators to work together towards new and affordable medicines for challenging diseases. Sixty-three post-doctoral fellows will spend 2-3 years developing open […]

Ribosome biosynthesis is one of the most multifaceted and energy-demanding processes in biology. It involves over 250 factors that transiently associate with the nascent pre-ribosome in a well-orchestrated manner. Importantly, increased ribosome biogenesis has a critical role in cancer initiation and progression. Owing to the advances in cryo-electron microscopy, this pathway’s detailed mechanism started to […]

Brain tumours, including ependymoma, are some of the most difficult cancers to treat. Although the past few years have seen many exciting advances in characterizing these brain tumours, there are few effective therapies available for patients, many of whom are children and young adults (and for whom long-term side effects can be extremely damaging). Until […]